The PIONeeR Project to Present Late-Breaking Results from its Phase Ib/IIa umbrella study at the ESMO Congress 2024
September 12 2024 - 4:21AM
The PIONeeR Project to Present
Late-Breaking Results from its Phase Ib/IIa umbrella study at the
ESMO Congress 2024
- The Presidential Symposium "Eyes to the
future" will feature the first-ever presentation of the clinical
trial portion of the PIONeeR Project (Precision
Immuno-Oncology for advanced
Non-Small Cell Lung Cancer
Patients with PD-(L)1 ICI
Resistance).
- PIONeeR is a major international
hospital-university research (RHU) project addressing the critical
challenge of resistance to PD-1(L1) immune checkpoint inhibitors
(ICIs) in patients with advanced non-small cell lung cancer
(NSCLC), including a biomarker program (> 400 biomarkers) and an
umbrella clinical trial (4 ICI combinations).
- The PIONeeR trial used an innovative
and adaptive design for trial reporting and decision making, to
identify signals of efficacy for novel ICI combinations in advanced
NSCLC patients progressing after PD-(L)1 inhibitors.
Marseille, France, Sept 12, 2024 – The PIONeeR
Project consortium today announced that Pr Pascale Tomasini,
Principal investigator of the PIONeeR early phase randomized
umbrella trial, will present the first data from the PIONeeR
Project’s clinical trial at the upcoming ESMO Congress 2024, to be
held September 13-17 in Barcelona, Spain, and virtually, during the
Presidential Symposium III: Eyes to the future.
" The PIONeeR trial is a collaborative success,
fighting on multiple fronts at once, with all the artillery at our
disposal, to explore how to overcome resistance to sequential or
concurrent PD-(L)1 inhibitors in advanced NSCLC. The clinical trial
is now complete, and we are conducting extensive biomarker analyses
that we hope will shed light on the path on how to address this
major challenge," said Prof. Fabrice BARLESI, coordinator
of the PIONeeR Project, General Director at Gustave Roussy and
Professor at Paris-Saclay University. "I would like to
highlight this incredible act of selflessness by our more than 450
patients enrolled in our biomarker part of the PIONeeR Project, and
our more than 150 patients being screened for inclusion in the
clinical trial portion of the study. We are grateful for the
dedication of our patients, which has taken us a giant step forward
in advancing this study.”
Details on the abstract accepted for presentation at ESMO
Congress 2024 include:
Presidential Symposium III: Eyes to the
future
- Title: Precision Immuno-Oncology for
advanced Non-small cell lung cancer (NSCLC) patients with PD-(L)1
inhibitors Resistance (PIONeeR): a phase Ib/IIa clinical trial
targeting identified resistance pathways
- Presentation Number: LBA8.
- Presenter: Pr Pascale Tomasini, Aix
Marseille Université, AP-HM, Early Phase Clinical Trials in
Oncology Unit, Principal investigator of the PIONeeR early phase
randomized clinical trial
- Presentation Time: Monday September 16,
2024, 4:30 - 6:15 pm CEST
Abstract will be available on the ESMO website:
ESMO Congress 2024 - Conference Calendar. All accepted abstracts
will be published in the ESMO Congress 2024 Abstract Book, a
supplement to the official ESMO journal, Annals of Oncology.
***About the PIONeeR Project
Winner of the 3rd University-Hospital Research
in Health call for projects in the “Investments for the Future
program”, the PIONeeR Project gathers over 100 scientists across 3
different countries, 8 research labs, and 16 hospitals, all
committed to the scientific, medical and human adventure that it
represents. The project has recruited 450+ patients to its
biomarker program and 114 patients to the PIONeeR Phase Ib/IIa
clinical trial. The clinical trial is now complete and extensive
biomarker analyses are ongoing. The partners of the PIONeeR Project
are Marseille Immunopôle (MI), Aix Marseille Université (amU),
Inserm, CNRS, 4 research & technology centers
(CIML, CRCM, CIPHE, MImAbs), Assistance Publique-Hôpitaux de
Marseille (AP-HM), the Paoli-Calmettes Institute, the Léon-Bérard
Center, Gustave Roussy Institute, and industrial partners
AstraZeneca, ImCheck Therapeutics, Innate Pharma and Veracyte.
This 7-year project1 has been granted a French public funding
(ANR-17-RHUS-0007).
Press contact:
Marie Puvieux, ATCG Partners, +33 6 10 54 36 72
communication@the-pioneer-project.org
1 Initially a 5-year project. Extension period granted, notably
linked to the Covid crisis.